SCHEMBL5015572

SCHEMBL5015572

COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)cnnc2cc1OCC1CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.53
PDGFRB P09619 2/20 0.53
EGFR P00533 5/20 0.47
FGFR1 P11362 5/20 0.47
FLT1 P17948 5/20 0.47
FLT4 P35916 5/20 0.47
RET P07949 2/20 0.47
MET P08581 2/20 0.47
KIT P10721 2/20 0.47
AXL P30530 2/20 0.47
TYRO3 Q06418 2/20 0.47
MERTK Q12866 2/20 0.47
PLK4 O00444 1/20 0.47
GAK O14976 1/20 0.47
EPHB6 O15197 1/20 0.47
RIPK2 O43353 1/20 0.47
ERN1 O75460 1/20 0.47
STK10 O94804 1/20 0.47
MAP4K4 O95819 1/20 0.47
CHEK2 O96017 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5015549 0.90 KDR (0.51) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL5025614 0.86 KDR (0.54) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL5025618 0.86 KDR (0.54) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL7129696 0.85 KDR (0.47) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL1401640 0.85 KDR (0.65) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL13998242 0.84 EGFR (0.42) KDREGFRFGFR1FLT1FLT4
SCHEMBL5017592 0.84 KDR (0.47) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL4451546 0.83 KDR (0.73) KDRPDGFRBEGFRFGFR1FLT1
SCHEMBL5015530 0.82 EGFR (0.42) KDREGFRFGFR1FLT1FLT4
SCHEMBL13998322 0.82 KDR (0.54) KDRPDGFRBEGFRFGFR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 EP claimed
US-6887874-B2 Cinnoline compounds ASTRAZENECA AB (SE) 2005-05-03 US claimed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 US claimed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 EP claimed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 WO claimed
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 EP disclosed
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 EP disclosed
US-6887874-B2 Cinnoline compounds ASTRAZENECA AB (SE) 2005-05-03 US disclosed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 EP disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 KDR 12/4885PDGFRB 514/4885EGFR 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.